Hotwire Ignite Possibility Program Introduces the First Group of Tech-enabled DEI Innovators
Hotwire, the leading global technology communications consultancy part of Enero Group, has announced the first set of participating companies in the Hotwire Ignite Possibility Program (HIPP). Launched earlier this year, HIPP is providing $1 million USD in pro bono brand marketing and public relations services to tech and tech-enabled organizations led by or supporting minority communities. This program is part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to amplify people and organizations creating meaningful and sustainable change in the world through technology innovation.
After a rigorous review process of nearly 100 applicants, including in-depth interviews with a short list of finalists, the first group of participating companies includes for-profit and nonprofit organizations in the consumer and B2B technology industries with headquarters in the United States and United Kingdom. HIPP participants from our other European offices and Australia will be announced in the coming months.
The six initial participating companies are:
- Children’s Creativity Musuem , a nonprofit organization offering hands-on, multimedia arts and technology experiences to build children’s creative confidence.
- Full Circle Fund , a nonprofit community leveraging professionals’ financial and intellectual capital to accelerate nonprofits and build a better San Francisco Bay Area.
- Go Flyy , an on-demand, same-day delivery and returns service for fashion, beauty and wellness products, currently operating in Los Angeles, New York City and Seattle.
- Husmus , an online service that aims to make renting easy and affordable in order to build a world where everyone can enjoy renting privately.
- Menther , a digital platform helping to empower and advance women globally through cross and intra-generational mentorship matching and support.
- Storyskimo , an online platform leveraging audio and podcasting as a language and learning development tool for children.
Additionally, as part of HIPP, our Spain office has launched an industry collaborative think tank, Margarita Bly , that is working to pave the way for more female communicators of science, technology and innovation, and encourage more girls and young women to pursue STEM careers.
“We are thrilled to announce the first class of participants in the Hotwire Ignite Possibility Program and look forward to supporting the communications goals of this impressive group of companies,” said Heather Kernahan, Global CEO, Hotwire. “This program is a critical part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to direct more of our resources towards the advancement of social justice in our industry.”
Teams from Hotwire’s global offices will be working with the selected organizations to address their specific business needs through customized programs that include brand strategy, marketing, and public relations services.
“We are honored to be selected as a HIPP participant and so excited to work with a world-class technology communications agency like Hotwire. Children’s Creativity Museum’s mission to nurture creativity and collaboration in all children and families, specifically those in socially and economically disadvantaged communities, is well-aligned with the program goals,” said Carol M. Tang, Ph.D., Executive Director, Children’s Creativity Museum. “We can’t wait to get started.”
“As a female minority co-founder who benefited from mentorship early on in my own career, I’m thrilled to be working with Hotwire to help us scale Menther so more women can have easy access to the power of mentorship,” said Vanessa Villaverde, Menther. “We know this partnership is going to be game changing for us in our reach and impact at a time when women who have been economically impacted by COVID-19 need support the most,” Menther Co-Founder Lesli Ott said.
“We truly believe that no matter who you are or what background you come from, you should be able to access safe and secure housing without having to worry about your credit history or the upfront costs involved,” said Sarah Wernér, Founder of Husmus. “The team and I have worked really hard to create a product that solves a big problem. However, we recognise while we have great technical experience, we do not have the marketing skills to make sure that we are able to reach the many people who need us. Working with Hotwire gives us access to expertise that we otherwise would not have at this early stage and we can’t wait to kick things off,” Husmus’ founder Sarah Wernér said.
About Hotwire
Hotwire is the global technology communication consultancy, part of the Enero Group. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation. www.hotwireglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005248/en/
Contact information
Kelsey Quickstad
kelsey.quickstad@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
